Apellis Pharmaceuticals, Inc. (APLS)
Largest Insider Buys in Sector
APLS Stock Price History Chart
APLS Stock Performance
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
Insider Activity of Apellis Pharmaceuticals, Inc.
Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $40.74M worth of Apellis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $10.16M and sold $35.15M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.
List of Insider Buy and Sell Transactions, Apellis Pharmaceuticals, Inc.
| 2025-01-13 | Sale | Chief Scientific Officer | 2,288 0.0019% | $28.70 | $65,670 | -0.80% | ||
| 2025-01-13 | Sale | Chief Executive Officer | 6,247 0.0051% | $28.70 | $179,302 | -0.80% | ||
| 2025-01-13 | Sale | General Counsel | 4,965 0.004% | $28.70 | $142,506 | -0.80% | ||
| 2025-01-13 | Sale | Chief Commercial Officer | 2,685 0.0022% | $28.70 | $77,065 | -0.80% | ||
| 2025-01-13 | Sale | Chief Financial Officer | 2,170 0.0018% | $28.70 | $62,284 | -0.80% | ||
| 2025-01-13 | Sale | Chief Business & Strat Officer | 1,599 0.0013% | $28.70 | $45,895 | -0.80% | ||
| 2025-01-13 | Sale | Chief Development Officer | 264 0.0002% | $28.70 | $7,577 | -0.80% | ||
| 2025-01-13 | Sale | Chief Technical Officer | 2,632 0.0021% | $28.70 | $75,544 | -0.80% | ||
| 2025-01-13 | Sale | Chief People Officer | 1,599 0.0013% | $28.70 | $45,895 | -0.80% | ||
| 2025-01-13 | Sale | VP/Chief Accounting Officer | 783 0.0006% | $28.70 | $22,474 | -0.80% | ||
| 2025-01-06 | Sale | Chief Medical Officer | 2,816 0.0022% | $33.81 | $95,215 | -16.20% | ||
| 2024-12-23 | Sale | Chief Development Officer | 63 <0.0001% | $33.09 | $2,085 | -1.60% | ||
| 2024-12-11 | Sale | General Counsel | 5,000 0.004% | $34.23 | $171,175 | -2.47% | ||
| 2024-09-16 | Sale | director | 37,000 0.0303% | $36.23 | $1.34M | -17.98% | ||
| 2024-09-16 | Sale | VP/Chief Accounting Officer | 192 0.0002% | $36.21 | $6,952 | -17.98% | ||
| 2024-09-03 | Sale | VP/Chief Accounting Officer | 550 0.0005% | $39.49 | $21,720 | -17.76% | ||
| 2024-06-21 | Sale | director | 37,000 0.028% | $39.24 | $1.45M | -11.68% | ||
| 2024-05-08 | Sale | Chief Scientific Officer | 78,907 0.0651% | $42.35 | $3.34M | -15.89% | ||
| 2024-04-08 | Sale | Chief Scientific Officer | 69,107 0.0577% | $54.17 | $3.74M | -29.90% | ||
| 2024-04-01 | Sale | Chief Financial Officer | 4,000 0.0033% | $58.66 | $234,640 | -36.39% |
Insider Historical Profitability
| Deschatelets Pascal | Chief Scientific Officer | 1138195 0.915% | $29.69 | 0 | 37 | |
| Francois Cedric | Chief Executive Officer | 307415 0.2471% | $29.69 | 0 | 30 | |
| Watson David O. | General Counsel | 107756 0.0866% | $29.69 | 0 | 18 | |
| Dunlop A. Sinclair | director | 100000 0.0804% | $29.69 | 0 | 25 | |
| Townsend Adam J. | Chief Commercial Officer | 90269 0.0726% | $29.69 | 0 | 21 | |
| Sullivan Timothy Eugene | Chief Financial Officer | 88100 0.0708% | $29.69 | 1 | 11 | +1.94% |
| DeLong Mark Jeffrey | Chief Business & Strat Officer | 58796 0.0473% | $29.69 | 0 | 19 | |
| Eisele Jeffrey | Chief Development Officer | 56881 0.0457% | $29.69 | 0 | 13 | |
| Baumal Caroline | Chief Medical Officer | 55560 0.0447% | $29.69 | 0 | 2 | |
| Nicholson Nur | Chief Technical Officer | 54156 0.0435% | $29.69 | 0 | 6 | |
| Lewis Karen | Chief People Officer | 45099 0.0363% | $29.69 | 0 | 12 | |
| Chopas James George | VP/Chief Accounting Officer | 37358 0.03% | $29.69 | 0 | 8 | |
| Morningside Venture Investments Ltd | 10 percent owner | 12806342 10.2951% | $29.69 | 9 | 0 | +6.91% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3579305 2.8774% | $29.69 | 1 | 0 | +31.35% |
| Hillhouse Capital Management, Ltd. | 10 percent owner | 3527152 2.8355% | $29.69 | 1 | 0 | +31.35% |
| Cormorant Asset Management, LLC | 10 percent owner | 3473925 2.7927% | $29.69 | 1 | 0 | +31.35% |
| Machiels Alec | director | 367420 0.2954% | $29.69 | 0 | 44 | |
| Grossi Federico | Chief Medical Officer | 94884 0.0763% | $29.69 | 0 | 43 | |
| SCHEIBLER LUKAS | Chief Research Officer | 68299 0.0549% | $29.69 | 1 | 12 | <0.0001% |
| Brown Victoria L. | Program Team Lead | 24974 0.0201% | $29.69 | 0 | 2 | |
| FONTEYNE PAUL R. | director | 5000 0.004% | $29.69 | 1 | 0 | +15.13% |
| Perry Nicole D | Vice President - Accounting | 4847 0.0039% | $29.69 | 0 | 10 |
Institutional Investor Ownership
| Wellington Management Company | $885.11M | 12.41 | 15.06M | -8.44% | -$81.54M | 0.15 | |
| Ecor1 Capital Llc | $667.59M | 9.36 | 11.36M | +1.65% | +$10.84M | 4.68 | |
| Avoro Capital Advisors Llc | $653.11M | 9.15 | 11.11M | 0% | +$0 | 7.83 | |
| The Vanguard Group | $558.75M | 7.83 | 9.51M | -0.52% | -$2.93M | 0.01 | |
| BlackRock | $322.97M | 4.53 | 5.49M | +2.11% | +$6.66M | 0.01 | |
| T Rowe Price Investment Management Inc | $270.73M | 3.8 | 4.61M | -26.93% | -$99.8M | 0.17 | |
| JENNISON ASSOCIATES LLC | $190.48M | 2.67 | 3.24M | -1.08% | -$2.08M | 0.13 | |
| State Street | $171.02M | 2.4 | 2.91M | -0.2% | -$346,449.32 | 0.01 | |
| Octagon Capital Advisors LP | $164.99M | 2.31 | 2.81M | 0% | +$0 | 0.9 | |
| T. Rowe Price | $144.56M | 2.03 | 2.46M | -0.04% | -$64,247.22 | 0.02 | |
| JPMorgan Chase | $130.16M | 1.82 | 2.21M | -13.98% | -$21.15M | 0.01 | |
| Fidelity Investments | $128.07M | 1.8 | 2.18M | +4.12% | +$5.07M | 0.01 | |
| Assenagon Asset Management S.A. | $118.95M | 1.67 | 2.02M | -5.66% | -$7.14M | 0.29 | |
| Boxer Capital, LLC | $101.45M | 1.42 | 1.73M | 0% | +$0 | 2.08 | |
| Geode Capital Management | $99.35M | 1.39 | 1.69M | +3.63% | +$3.48M | 0.01 | |
| Morgan Stanley | $96.26M | 1.35 | 1.64M | -47.13% | -$85.79M | 0.01 | |
| Deutsche Bank | $94.74M | 1.33 | 1.61M | +88.07% | +$44.37M | 0.04 | |
| Artal Group S A | $77.31M | 1.08 | 1.32M | -7.46% | -$6.23M | 0.34 | |
| OrbiMed | $76.28M | 1.07 | 1.3M | +40.73% | +$22.08M | 0.59 | |
| Citadel Advisors LLC | $69.72M | 0.98 | 1.19M | +316% | +$52.96M | 0.04 | |
| Polar Capital | $61.98M | 0.87 | 1.05M | +0.1% | +$58,780.00 | 0.34 | |
| Deep Track Capital Lp | $58.78M | 0.82 | 1M | New | +$58.78M | 0.27 | |
| Fiera Capital | $55.75M | 0.78 | 948,437 | +3.19% | +$1.73M | 0.16 | |
| Charles Schwab | $54.35M | 0.76 | 924,562 | +2.23% | +$1.18M | 0.01 | |
| Frazier Life Sciences Management L P | $52.03M | 0.73 | 885,165 | 0% | +$0 | 2.35 | |
| HERITAGE ASSET MANAGEMENT INC | $50.49M | 0.7 | 845,533 | +89.58% | +$23.86M | 0.26 | |
| Logos Global Management Lp | $47.02M | 0.66 | 800,000 | -15.79% | -$8.82M | 5.08 | |
| Millennium Management LLC | $46.17M | 0.65 | 785,396 | +6,169.63% | +$45.43M | 0.03 | |
| Invesco | $44.8M | 0.63 | 762,115 | +46.89% | +$14.3M | 0.01 | |
| Bank of America | $42.52M | 0.6 | 723,444 | +66.56% | +$16.99M | <0.01 | |
| Candriam S C A | $34.38M | 0.48 | 584,925 | +73.31% | +$14.54M | 0.22 | |
| Iron Triangle Partners LP | $32.33M | 0.45 | 550,000 | New | +$32.33M | 3.44 | |
| Ameriprise Financial | $31.23M | 0.44 | 531,362 | -6.05% | -$2.01M | 0.01 | |
| Driehaus Capital Management LLC | $29.57M | 0.41 | 503,039 | +4.47% | +$1.27M | 0.29 | |
| Voya Investment Management LLC | $29.08M | 0.41 | 494,692 | +92.84% | +$14M | 0.03 | |
| Victory Capital Management Inc | $28.91M | 0.41 | 491,897 | -20.18% | -$7.31M | 0.03 | |
| Bellevue Group | $27.86M | 0.39 | 473,915 | -42.33% | -$20.45M | 0.43 | |
| Td Asset Management Inc | $27M | 0.38 | 459,402 | -4.95% | -$1.41M | 0.02 | |
| Northern Trust | $25.89M | 0.36 | 440,456 | -1.84% | -$486,110.61 | <0.01 | |
| First Trust | $23.89M | 0.34 | 406,483 | +332.58% | +$18.37M | 0.02 | |
| Cormorant Asset Management Lp | $23.51M | 0.33 | 400,000 | -36% | -$13.23M | 1.1 | |
| New York State Common Retirement Fund | $19.16M | 0.27 | 325,926 | -4.28% | -$857,074.30 | 0.03 | |
| BNY Mellon | $18.98M | 0.27 | 322,922 | -13.25% | -$2.9M | <0.01 | |
| Goldman Sachs | $18.78M | 0.26 | 319,476 | +2.86% | +$522,730.59 | <0.01 | |
| Nuveen | $15.9M | 0.22 | 270,576 | +0.02% | +$3,291.68 | 0.01 | |
| Point72 Asset Management | $15.74M | 0.22 | 267,823 | New | +$15.74M | 0.02 | |
| Citigroup | $15.38M | 0.22 | 261,708 | +202.41% | +$10.3M | 0.01 | |
| Ensign Peak Advisors Inc | $15.3M | 0.21 | 260,274 | +5.99% | +$864,536.26 | 0.03 | |
| Amundi | $11.81M | 0.21 | 248,483 | +2.95% | +$337,891.11 | 0.01 | |
| Prudential Financial | $14.43M | 0.2 | 245,560 | -24.8% | -$4.76M | 0.02 |